Updated September 21, 2026
The average analyst price target for Novo Nordisk A/S is $46.98 on a 12-month horizon. With the stock trading at $43.41, that leaves upside of +8.2%.
We define the fair-value range as ±10% of the price target, because price targets are estimates, not exact values. For Novo Nordisk A/S the range runs from $42.28 to $51.68 — which means the stock is considered fairly valued.
Our overall score for Novo Nordisk A/S is 70/100 (value 83, quality 89, momentum 37). The price target shows where the analysts expect the price to go — our score shows how the company is doing right now. The strongest setup is when both point in the same direction.
The average analyst price target for Novo Nordisk A/S is $46.98 on a 12-month horizon. The current price is $43.41, which leaves upside of +8.2%. On that basis the stock is considered fairly valued.
The fair-value range (±10% of the price target) for Novo Nordisk A/S runs from $42.28 to $51.68. The price currently sits inside the range – the stock is considered fairly valued.
A price target is the analysts' estimate of where the stock could be in 12 months – not a promise. Analysts often adjust their targets only after the price has already moved, so big turning points are sometimes missed. Use the price target as a reference point together with the technical signal as well as the key figures – never as a guarantee.
The price target is the average of the analysts' 12-month price targets (Wall Street consensus), refreshed daily from our data sources – together with the price, the signal, plus the key figures.
The price target is the average of the analysts' 12-month price targets (Wall Street consensus), updated daily. Analysis framework by Troels Højbjerg, the creator of WallStreetBuys. WallStreetBuys does not offer investment advice – trading stocks carries a risk of losses.